Revance Therapeutics, Inc. (RVNC): Curtis Ruegg , EVP, Technical Operations of Revance Therapeutics, Inc. sold 1,000 shares on Jun 13, 2016. The Insider selling transaction was reported by the company on Jun 15, 2016 to the Securities and Exchange Commission. The shares were sold at $18.25 per share for a total value of $18,250.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 11, 2016, Curtis Ruegg (EVP, Technical Operations) sold 1,000 shares at $16.18 per share price.On Nov 18, 2015, Arthur Peter Bertolino (EVP and Chief Medical Officer) sold 7,753 shares at $39.33 per share price.
Revance Therapeutics Inc: On Wednesday, Jun 15, 2016 heightened volatility was witnessed in Revance Therapeutics Inc which led to swings in the share price. The shares opened for trading at $13.13 and hit $14.6 on the upside , eventually ending the session at $14.16, with a gain of 7.19% or 0.95 points. The heightened volatility saw the trading volume jump to 7,77,098 shares. The 52-week high of the share price is $42.41 and the company has a market cap of $403 M . The 52-week low of the share price is at $12.93.
Company has been under the radar of several Street Analysts.Revance Therapeutics Inc is Downgraded by Brean Capital to Hold. Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Jun 14, 2016.Revance Therapeutics Inc is Reiterated by Piper Jaffray to Overweight while Lowering the Price Target of the company shares to $ 35 from a previous price target of $54 . The Rating was issued on Jun 14, 2016.Revance Therapeutics Inc is Reiterated by SunTrust to Buy while Lowering the Price Target of the company shares to $ 22 from a previous price target of $46 . The Rating was issued on Jun 14, 2016.Revance Therapeutics Inc is Initiated by Sun Trust Rbsn Humphrey to Buy and the brokerage firm has set the Price Target at $46. The Rating was issued on Mar 23, 2016.
Revance Therapeutics Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on the development manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through two dose formulations topical product candidate RT001 and injectable product candidate RT002. RT001 is a non-injectable dose form. RT001 is being studied for aesthetic indications such as crow’s feet lines (wrinkles around the eyes) and therapeutic indications such as hyperhidrosis (excessive sweating). It is in a Phase III development program of RT001 in North America for the treatment of crow’s feet lines. RT002 is an injectable formulation of botulinum toxin designed to be targeted and longer lasting. RT002 is being studied for aesthetic indications such as glabellar (frown) lines and therapeutic uses such as muscle movement disorders.